|
1
|
Lee SY and Jeoung D: The reverse
proteomics for identification of tumor antigens. J Microbiol
Biotechnol. 17:879–890. 2007.PubMed/NCBI
|
|
2
|
Fernández Madrid F, Tang N, Alansari H,
Karvonen RL and Tomkiel JE: Improved approach to identify
cancer-associated autoantigens. Autoimmun Rev. 4:230–235. 2005.
|
|
3
|
Rhee SG: Cell signaling.
H2O2, a necessary evil for cell signaling.
Science. 312:1882–1883. 2006.PubMed/NCBI
|
|
4
|
Rhee SG, Chae HZ and Kim K:
Peroxiredoxins: a historical overview and speculative preview of
novel mechanisms and emerging concepts in cell signaling. Free
Radic Biol Med. 38:1543–1552. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Neumann CA, Cao J and Manevich Y:
Peroxiredoxin 1 and its role in cell signaling. Cell Cycle.
8:4072–4078. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cao J, Schulte J, Knight A, et al: Prdx1
inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J.
28:1505–1517. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoshino I, Matsubara H, Akutsu Y, et al:
Tumor suppressor Prdx1 is a prognostic factor in esophageal
squamous cell carcinoma patients. Oncol Rep. 18:867–871.
2007.PubMed/NCBI
|
|
8
|
Zhang J, Wang K, Zhang J, Liu SS, Dai L
and Zhang JY: Using proteomic approach to identify tumor-associated
proteins as biomarkers in human esophageal squamous cell carcinoma.
J Proteome Res. 10:2863–2872. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim YJ, Lee WS, Ip C, Chae HZ, Park EM and
Park YM: Prx1 suppresses radiation-induced c-Jun NH2-terminal
kinase signaling in lung cancer cells through interaction with the
glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex.
Cancer Res. 66:7136–7142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim JH, Bogner PN, Baek SH, et al:
Up-regulation of peroxiredoxin 1 in lung cancer and its implication
as a prognostic and therapeutic target. Clin Cancer Res.
14:2326–2333. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang JW, Lee SH, Jeong JY, et al:
Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small
cell lung cancer. FEBS Lett. 579:2873–2877. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yonglitthipagon P, Pairojkul C, Chamgramol
Y, et al: Prognostic significance of peroxiredoxin 1 and
ezrin-radixin-moesin-binding phosphoprotein 50 in
cholangiocarcinoma. Hum Pathol. 43:1719–1730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Yang ZL, Ren X, et al: ILK and PRDX1
are prognostic markers in squamous cell/adenosquamous carcinomas
and adenocarcinoma of gallbladder. Tumour Biol. 34:359–368. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Quan C, Cha EJ, Lee HL, Han KH, Lee KM and
Kim WJ: Enhanced expression of peroxiredoxin I and VI correlates
with development, recurrence and progression of human bladder
cancer. J Urol. 175:1512–1516. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Riddell JR, Bshara W, Moser MT, Spernyak
JA, Foster BA and Gollnick SO: Peroxiredoxin 1 controls prostate
cancer growth through Toll-like receptor 4-dependent regulation of
tumor vasculature. Cancer Res. 71:1637–1646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chung KH, Lee DH, Kim Y, et al: Proteomic
identification of overexpressed PRDX 1 and its clinical
implications in ovarian carcinoma. J Proteome Res. 9:451–457. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gordis L: Assessing the validity and
reliability of diagnostic and screening tests. Epidemiology.
3:71–94. 1996.
|
|
18
|
Das S, Otani H, Maulik N and Das DK: Redox
regulation of angiotensin II preconditioning of the myocardium
requires MAP kinase signaling. J Mol Cell Cardiol. 41:248–255.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kamata H, Honda S, Maeda S, Chang L,
Hirata H and Karin M: Reactive oxygen species promote TNFα-induced
death and sustained JNK activation by inhibiting MAP kinase
phosphatases. Cell. 120:649–661. 2005.
|
|
20
|
Wen ST and Van Etten RA: The PAG gene
product, a stress-induced protein with antioxidant properties, is
an Abl SH3-binding protein and a physiological inhibitor of c-Abl
tyrosine kinase activity. Genes Dev. 11:2456–2467. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Neumann CA, Krause DS, Carman CV, et al:
Essential role for the peroxiredoxin Prdx1 in erythrocyte
antioxidant defence and tumour suppression. Nature. 424:561–565.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Benhar M, Dalyot I, Engelberg D and
Levitzki A: Enhanced ROS production in oncogenically transformed
cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated
protein kinase activation and sensitization to genotoxic stress.
Mol Cell Biol. 21:6913–6926. 2001. View Article : Google Scholar
|
|
23
|
Barranco-Medina S, Lázaro JJ and Dietz KJ:
The oligomeric conformation of peroxiredoxins links redox state to
function. FEBS Lett. 583:1809–1816. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sirvent A, Benistant C and Roche S:
Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and
cancer cells. Biol Cell. 100:617–631. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mu ZM, Yin XY and Prochownik EV: Pag, a
putative tumor suppressor, interacts with the Myc Box II domain of
c-Myc and selectively alters its biological function and target
gene expression. J Biol Chem. 277:43175–43184. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hoskins ER, Hood BL, Sun M, Krivak TC,
Edwards RP and Conrads TP: Proteomic analysis of ovarian cancer
proximal fluids: validation of elevated peroxiredoxin 1 in patient
peripheral circulation. PLoS One. 6:e250562011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hoshino I, Matsubara H, Hanari N, et al:
Histone deacetylase inhibitor FK228 activates tumor suppressor
Prdx1 with apoptosis induction in esophageal cancer cells. Clin
Cancer Res. 11:7945–7952. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen MF, Keng PC, Shau H, et al:
Inhibition of lung tumor growth and augmentation of
radiosensitivity by decreasing peroxiredoxin I expression. Int J
Radiat Oncol Biol Phys. 64:581–591. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu H, Zhang J, Wang S, et al: Screening
of autoantibodies as potential biomarkers for hepatocellular
carcinoma by using T7 phase display system. Cancer Epidemiol.
36:82–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Backes C, Ludwig N, Leidinger P, et al:
Immunogenicity of autoantigens. BMC Genomics. 12:3402011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tan EM and Zhang J: Autoantibodies to
tumor-associated antigens: reporters from the immune system.
Immunol Rev. 222:328–340. 2008. View Article : Google Scholar : PubMed/NCBI
|
